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Bordetella pertussis, the causative agent of whooping cough, has
many well-studied virulence factors and a characteristic clinical
presentation. Despite this information, it is not clear how B.
pertussis interaction with host cells leads to disease. In this study,
we examined the interaction of B. pertussis with a human bronchial
epithelial cell line (BEAS-2B) and measured host transcriptional
profiles by using high-density DNA microarrays. The early tran-
scriptional response to this pathogen is dominated by altered
expression of cytokines, DNA-binding proteins, and NFkB-regu-
lated genes. This previously unrecognized response to B. pertussis
was modified in similar but nonidentical fashions by the antiin-
flammatory agents dexamethasone and sodium salicylate. Cyto-
kine protein expression was confirmed, as was neutrophil che-
moattraction. We show that B. pertussis induces mucin gene
transcription by BEAS-2B cells then counters this defense by using
mucin as a binding substrate. A set of genes is described for which
the catalytic activity of pertussis toxin is both necessary and
sufficient to regulate transcription. Host genomic transcriptional
profiling, in combination with functional assays to evaluate sub-
sequent biological events, provides insight into the complex in-
teraction of host and pathogen.
Bordetella pertussis is a Gram-negative coccobacillus and thecausative agent of whooping cough in humans. It is a
well-studied pathogen with a number of potent virulence factors.
However, little is known about the responses elicited by this
organism in human cells, especially at the level of gene
transcription.
Autopsy studies of pertussis victims performed in the early 20th
century revealed a diffuse bronchopneumonia with increased se-
cretion of mucus, associated with airway plugging and atelectasis
(1). Bacteria were seen tightly packed between the cilia of epithelial
cells, which desquamated during infection. Rodent models of
Bordetella pertussis infection have revealed infiltrates of monocytes,
neutrophils, and lymphocytes in the lung (2).
B. pertussis expresses several virulence factors directed at the
host epithelium. Filamentous hemagglutinin is the major adhesin
of B. pertussis for bronchial epithelial cells (3). B. pertussis also
produces several toxins, including pertussis toxin (PT). PT is
associated with a panoply of biological effects, many of which are
linked to its ADP–ribosyltransferase activity. ADP ribosylation
of the Ga family of host proteins prevents their usual regulatory
response to G-protein-linked receptor engagement (4). B. per-
tussis also secretes an adenylate cyclase toxin that enters host
cells and raises intracellular cAMP concentrations (5). Tracheal
cytotoxin (TCT), a muramyl tetrapeptide bacterial cell wall
fragment, in combination with lipopolysaccharide, paralyzes
respiratory epithelial cilia and ultimately causes cell death and
extrusion through pathways involving IL-1 and nitric oxide
synthase (iNOS) (6). The molecular mechanisms through which
B. pertussis exerts these effects and by which host cells attempt
to counter this pathogenic strategy remain largely undescribed.
The goal of this study was to understand the pathology caused
by B. pertussis and to explore whether early transcriptional
responses reveal pathogenic mechanisms and pathology at a
molecular level. Our approach involved genome-wide expression
analysis of a human bronchial epithelial cell line exposed to B.
pertussis, coupled with functional analyses.
Materials and Methods
Bacterial Strains, Toxins, and Cell Lines. Wild-type B. pertussis BP536
(3) and an isogenic derivative expressing a catalytically inactive PT,
BP-9Ky129G (7), were grown at 37°C on Bordet–Gengou agar
(Difco), supplemented with sheep blood (13% vyv) and 100 mgyml
streptomycin. Bordetellae were suspended in Eagle’s minimal
essential medium (EMEM) without FCS overnight at 37°C in 5%
CO2. They were then added to 2 3 107 epithelial cells at a ratio of
50 bacteria per cell. Purified wild-type and catalytically inactive PT
(7) were added to 2 3 107 epithelial cells at a concentration of 1
mgyml. The SV40-transformed human bronchial epithelial cell-line
BEAS-2B (8) was grown in EMEM with 10% FCS at 37°C in 5%
CO2. A human colon carcinoma cell line, HM3, was stably trans-
fected with a construct of the MUC2 or MUC5AC promoter fused
to a luciferase reporter gene. Transfected cells were maintained in
DMEM with high glucose and 10% FCS.
Infection Scheme. BEAS-2B cells (1–1.5 3 107) were incubated for
8 h, then some were treated for 1 hr with 10 mM sodium
salicylate or 1 mM dexamethasone. The cells were then infected
with B. pertussis, exposed to PT, or mock infected, and incubated
at 37°C for 3 h. Cells were washed with Hanks’ balanced salt
solution (HBSS), released from the flask with 5 mM EDTA in
HBSS, pelleted at 200 3 g for 5 min and frozen at 280°C.
Microarray Expression Analysis. Total RNA was extracted from cell
pellets by using Trizol (Life Technologies, Rockville, MD) and
purified by using an affinity resin (RNeasy, Qiagen, Chatsworth,
CA). Microarray analysis was performed according to the Af-
fymetrix Expression Analysis Technical Manual with the follow-
ing exceptions (see http:yyrelman.stanford.edu): first-strand
cDNA synthesis was performed at 42°C, and 10 mg of total RNA
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Table 1. Epithelial cell transcriptional profile after exposure to B. pertussis
Down-regulated transcripts Up-regulated transcripts
Ratio Accession no. GDByother names Ratio Accession no. GDByother names
ChemokinesyCytokines
122.38 X54489 GRO1ySCYB1yMGSA
116.29 M28130 IL8
19.11 Y00787 IL8
16.80 X04500 IL1B
16.47 NyA MCP1ySCYA2
M57731 GRO2ySCYB2yMIP-2a
X04602 IL6yIFNB2
M23178 SCYA3yMIP-1a
X53800 GRO3ySCYB3yMIP-2a
Transcription factorsyZn-finger proteins
23.03 X51435 ZNF40yHIVEP1 17.39 M59465 TNFAIP3yA20
D88613 HGCMyGCMA X65663 SOX6
U10324 ILF3yNF90 M82882 ELF1yE74-like factor
NyA MYBL1yA-MYB U69127 FUBP3y(FUSE)-binding protein 3
X59244 ZNF43yzinc-finger protein U18259 MHC2TAyCIITA-8
X55544 ATF1yTREB36
M29581 ZNF8yzinc-finger protein 8
M96843 ID2yinhibitor DNA binding
U78722 ZNF165yzinc-finger protein
U28687 ZNF157yzinc-finger protein
NyA BTF3 homologue
Secreted molecules
U19557 SCCA2yprotease Inhibitor 14.59 M57730 EFNA1yLERK1yB61yEphrin A1
U90546 BTN3A2ybutyrophilin M31166 PTX3ypentaxin-relatedyTSG-14
X64877 HFL3yH factor complement X57579 INHBAyinhibin, b Ayactivin
S75256 LCN2ylipocalin 2 X75308 MMP13ycollagenase 3
M21642 AT3yantithrombin III M31551 PAI2yplasminogen active inhibitor
ERyGolgi associated
X97064 SEC23A L10333 RTN1yreticulon 1
X71661 LMAN-1yERGIC-53ylectin U27326 FUT3yfucosyltransferase 3
L41390 acetylglucosaminyltransfer
U14550 STHMysialyltransferase
Metabolicysynthetic
23.44 AC002115 COX6Bycytochrome c oxid. D38524 Cytosolic purine 59-nucleotidase
M61853 CYP2C17yP450IIC17 X78711 GKyglycerol kinase deficiency
M60891 URODydecarboxylase M61855 CYP2C9ycytochrome P450, IIc
D49488 TTPAytocopherol a transfer Z94753 ATP7AyCu11 ATPase
U75362 USP13yubiquitin protease
S72370 PCypyruvate carboxylase
X59834 GLULyglutamine synthase
M84424 CTSEycathepsin E
M64082 FMO1ymonooxygenase 1
D28791 PIGAyphosphate inositol glycan
D10040 FACL1yfatty-acid-coA ligand
Cell surface moleculesyReceptors
24.76 M32315 TNFRSF1ByTNF receptor 2 14.53 Y00285 IGF2RyIGF II receptor
23.85 NyA PSG11yglycoprotein 14.30 M24283 ICAM1yCD54
L36531 ITGA8yintegrin alpha 8 13.27 U92971 F2RL2ythrombin receptor-like
M23197 CD33 S59184 RYKyreceptor tyrosine kinase
U64871 GPR19yG protein-coupled K02405 HLA-DQB1yHLA-DC-3 b
U04811 TROyTrophinin U11878 CXCR2yIL8RByIL-8 receptor
Y09392 TNFRSF12yAPO-3yTNFR U65011 PRAMEyantigen of melanoma
X16983 ITGA4yCD49Dyintegrin
U61500 TMEM1yEHOC-1
X77753 M1S1yTROP-2yGA733-1
S67798 SPAM1ysperm adhesion
D31784 CDH6ycadherin-6
S83249 NG-TRAyhormone pump
U80811 EDG2yG-protein-coupled
Cytoskeleton
L07261 ADD1ya adducin 1 L20826 PLS1yI-plastin
U34301 Nonmuscle myosin heavy chain
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was used. Triton X-100 (0.01%) was used in hybridization
solutions and buffers instead of Tween 20. Labeled cRNA (20
mg) was hybridized to Affymetrix HU6800 GENECHIP microar-
rays (Affymetrix, Santa Clara, CA) for 18 h in buffer without
EDTA. The arrays were rinsed with 63 standard saline phos-
phateyEDTA (SSPET, 0.18 M NaCly10 mM phosphate, pH
7.4y1 mM EDTA), washed in 0.13 Mes at 50°C for 30 min on
a rotisserie at 60 rpm, and then rinsed in 13 Mes. Hybridized
RNA was fluorescently labeled by incubation in streptavidin-
R-phycoerythrin conjugate (Molecular Probes) staining buffer
at 40°C for 15 min, then washed with 63 SSPET at 22°C.
Quantitative analysis of hybridization patterns and intensities
were performed as previously described (9) (see http:yy
relman.stanford.edu).
Cytokine and Apoptosis Quantitation. For cytokine analysis, 96-well
plates were coated with 0.2 mg of capture mAb (MAB 279, 206,
208, R&D Systems) and then blocked with 1% BSA in PBS. One
hour later, 10 ng of a biotinylated polyclonal Ab (BAF 279, 206,
208, R&D Systems) was added for 1 h. After washing, bound Ab
was detected by using a streptavidin–horseradish peroxidase
conjugate and tetramethylbenzadine substrate. Cytoplasmic
histone-associated DNA fragments were quantitated as a mea-
sure of apoptosis by using the Cell Death Detection ELISA Plus
kit per manufacturer recommendations (Roche Diagnostics).
Neutrophil Chemotaxis. Whole human blood was mixed 1:1 with
dextran in PBS for 45 min at 25°C. The top layer was overlaid on
Ficoll–Paque (Amersham Pharmacia) and centrifuged at 450 3 g
for 45 min, then granulocytes were harvested. RBCs were lysed
in hypotonic saline. Neutrophil purity was .95%. One hundred
thousand neutrophils were placed on a 3-mm filter (Neuroprobe,
Cabin John, MD) separating them from 29 ml of BEAS-2B
supernatant in a 96-well microchamber. In some wells, anti-
human IL-8 Ab was added at 10 mgyml for the duration of the
experiment (MAB208, R&D Systems). After 1 h at 37°C, only
cells that had passed through the filter were quantified by using
the CyQuant Cell Proliferation Kit (Molecular Probes).
Mucin Transcription and Binding. HM3 cells (1.5–3 3 106) carrying
either a MUC2 or MUC5AC promoter fusion to a luciferase
reporter gene were infected with B. pertussis in DMEM without
FCS in triplicate. After 2, 4, and 6 h, the cells were lysed for 30
min with 100 ml Reporter Lysis Buffer (Luciferase Assay System,
Promega) and then frozen at 280°C. The luciferase assay was
carried out per manufacturer recommendations.
For binding, 2.5 mg of bovine submaxillary mucin type I-S
(Sigma) was desiccated onto a microtiter plate at 37°C. Mucin-
treated and -untreated plates were then washed with PBS and
blocked with 5% dried nonfat milk in PBS for 1 h at 37°C and again
washed with PBS. A suspension of B. pertussis labeled with a
250-mgyml solution of FITC for 20 min was then added to the plates
for 1 h. Approximately 2.5 3 108 of labeled bacteria were added per
well. Nonadherent bacteria were washed away with three cycles of
PBS washings. Plates were then read in a 96-well fluorimeter.
Results
The Transcriptional Profile of BEAS-2B Cells Infected with B. pertussis
Reveals the Basis of Inflammation in Pertussis. Although the pathol-
ogy of pertussis has been studied for decades, little is known about
the response of individual cell types to infection. We examined the
genome-wide transcriptional responses of a bronchial epithelial cell
line, BEAS-2B (8), after infection with a wild-type B. pertussis strain
(BP536) for 3 h. Preliminary analyses had shown more robust
responses after 3 h than after 1 h (data not shown). Steady-state
transcript abundance for approximately 6,800 human genes was
analyzed in duplicate experiments. Reproducibility of the data was
examined by using duplicate preparations of labeled cDNAycRNA
from RNA isolated from each of two replicate infection experi-
ments. These analyses revealed 19.5% and 26.9% variation in mean
average difference values for all probe sets in the four comparisons.
The complete data sets for these (Table 2) and other experiments
(Tables 3–8) are available at http:yyrelman.stanford.edu.
Table 1 categorizes the named BEAS-2B genes that exhibited
greater than a 3-fold change in steady-state transcript abundance
after 3 h of infection. These results are noteworthy for the modest
number of genes that responded to B. pertussis exposure, unlike the
responses observed at later time points during human cytomega-
lovirus (10) and HIV-1 infections (J. Corbeil, D. Genini, D.
Sheeter, S. Rought, L. Leoni, P. Du, M. Ferguson, D. R. Masys, J. B.
Welsh, J. L. Fink, et al., personal communication). Of the 33 genes
whose expression levels increased in abundance by greater than
3-fold on B. pertussis infection, the most well-represented category
(8) was a group encoding proinflammatory cytokines. None of
these had been previously implicated in B. pertussis infection, but
their known chemoattractant activities are consistent with the
cellular infiltrate seen in pertussis. Our data also revealed increased
IL-1b transcription. IL-1 is known to increase growth-regulated
oncogene (GRO) mRNA and has been shown to play a role in
Table 1. Continued
Down-regulated transcripts Up-regulated transcripts
Ratio Accession no. GDByother names Ratio Accession no. GDByother names
Intracellular signaling
U48736 PRP4hyser-thr protein kinase 13.47 L42373 PPP2R5Ayprotein phosphatase
M38258 RARGyretinoic acid receptor 13.27 M69043 NFKBIAyIKBAyMAD-3
U18671 STAT2 U77129 MAP4K5yKHS1ykinase
M35416 RALByv-ral homolog B M80563 S100A4yCAPL calcium binding
U40371 PDE1Cyphosphodiesterase U37546 API2yIAP homolog CyMIHC
U77845 hTRIPyTRAF-interacting
X78549 PTK6yBRK
U20158 LCP2ySLP-76
U17327 NOS1ynitric oxide synthase
DNA replicationytranscription
U01833 NUBP1ynucleotide binding 13.31 NyA POLEyDNA polymerase, «
U47414 CCNG2ycyclin G2 X54993 TBPyTFIIDyTATA box binding
D26528 DDX7yRNA helicase X95152 BRCA2ybreast cancer 2
The experiment was repeated twice independently; data from one experiment are shown. Absolute difference ratios above or below the uninfected
transcription are not reported when one of the two values was less than 2-fold the background noise level.
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TCT-mediated respiratory epithelial cell toxicity (11, 12). Other
up-regulated gene products, such as IkB, are involved in NFkB
signaling and may regulate these cytokines (13).
The data in Table 1 reveal regulation of several apoptosis-related
genes. TNFAIP3 and API2 are antiapoptotic factors whose genes
are transcriptionally up-regulated by infection (14, 15). Further-
more, transcription of BTF3, a transcription factor associated with
apoptosis, is decreased (16). Given that monocytes and neutrophils
have been described to undergo apoptosis in response to B. pertussis
infection (17), we looked for evidence of apoptosis in B. pertussis-
infected BEAS-2B cells by using an ELISA assay for mono- and
oligonucleosomes at the 3-h time point used in the microarray
experiments. Representative data from duplicate experiments re-
vealed no evidence of apoptosis [absorbance of 0.028 6 0.005
(mean 6 95% confidence interval) for the infected cells and
0.029 6 0.005 for the uninfected cells (P 5 0.85)].
The 65 genes whose expression levels decreased by greater
than 3-fold included those encoding 10 transcription factors and
6 cellular adhesion molecules. The overall transcriptional profile
of these infected cells suggested a picture of relatively rapid
activation and defensive host responses.
The ADP–Ribosyltransferase Activity of PT Is Responsible for Specific
Transcriptional Responses. To define the role of PT ADP–ribosylase
activity at the transcriptional level, we compared the responses of
BEAS-2B cells to two pairs of stimuli: (i) wild-type PT vs. a
catalytically inactive but properly folded PT holotoxin (9Ky129G),
and (ii) wild-type B. pertussis vs. an isogenic derivative that ex-
presses PT-9Ky129G. Data sets are available as Tables 3 and 4 at
http:yyrelman.stanford.edu; Table 5 lists genes whose expression
changed more than 3-fold when comparing the effects of both the
purified inactive toxin with wild-type toxin and the toxin-mutant
strain with its isogenic parent strain. Thus, these host cell genes
represent those for which pertussis toxin enzymatic activity was
both necessary and sufficient to effect a change in transcript
abundance. Several of these genes are G-protein or cAMP regu-
lated, such as those encoding matrix metalloproteinase 1, b B1-
crystallin, basic fibroblast growth factor, and the Na1yCl2-
dependent serotonin transporter. Surprisingly, other genes such as
the serumyglucocorticoid-regulated kinase, whose expression level
decreased, and guanylate cyclase 1, whose expression level in-
creased, showed responses in directions contrary to those suggested
by the literature. The majority of the PT-response genes revealed
in these experiments had not been previously associated with
G-protein activity. Thirty-eight genes with discordant 3-fold
changes, suggesting an effect of PT activity that depends on other
bacterial factors, are highlighted (Table 6) at http:yyrelman.
stanford.edu.
The Chemokine Response of B. pertussis-Infected Epithelial Cells
Overcomes the Antichemotactic Activity of PT. The known activities
of PT and other B. pertussis virulence factors such as adenylate
cyclase toxin suggest that they might be capable of blocking the
chemotactic response predicted by our data (18). We first docu-
mented the predicted protein expression responses for several of
the cytokine genes that were induced in BEAS-2B cells. Fig. 1a
shows an increase in secreted IL-8 from 35 6 0.8 (mean 6 95%
confidence interval) to 678 6 78 ngyml (P 5 0.0006) and MCP-1
from 580 6 29 to 3367 6 349 ngyml (P 5 0.004) (Fig. 1b) when the
supernatants of BEAS-2B cells were harvested after 24 h of
exposure to B. pertussis or mock infection. Induction of IL-6
secretion was also confirmed, with none detectable in uninfected
supernatants, whereas 116 6 2 ngyml was detected in supernatants
from infected cells (P , 2.5 3 1027) (Fig. 1c).
IL-8 and the GRO family of chemokines are strong neutrophil
chemoattractants that have not been previously associated with B.
pertussis infection (19, 20). We examined the chemoattractant
activity of the BEAS-2B cell supernatants by using a neutrophil
migration assay, in which cells are separated from BEAS-2B
supernatants by a porous membrane. As shown in Fig. 1d, 2.9-fold
more neutrophils were attracted to the supernatant of infected cells
than to that of uninfected cells. Furthermore, cell migration could
be partially inhibited (34% with the infected cell supernatant) by
using an anti-IL-8 mAb, suggesting that IL-8 contributes to this
chemoattractant activity and indicating a role for other chemokines
as well. Although previous reports suggest that PT is capable of
inhibiting neutrophil chemotaxis in vitro (21), chemoattraction was
the dominant effect in this experimental system.
Antiinflammatory Drugs Suppress the Epithelial Cell Responses to B.
pertussis. The data presented above and in Table 1 reveal up-
regulation of genes whose products play a role in NFkB activation
as well as genes known to be regulated by NFkB. We hypothesized
that pretreatment of the epithelial cells with antiinflammatory
drugs that interfere with NFkB activation could help confirm
mechanisms by which B. pertussis stimulates a proinflammatory
cellular response. Dexamethasone was chosen because glucocorti-
coids have been suggested as a therapy for pertussis, despite the
paucity of supportive data (22). Glucocorticoids may inhibit NFkB
activity by augmenting IkB synthesis or through association of their
bound receptors to NFkB (23). Sodium salicylate inhibits NFkB
activation of genes by preventing phosphorylation of IkB (24).
The transcriptional responses of BEAS-2B cells pretreated with
either sodium salicylate or dexamethasone and then exposed to B.
pertussis BP536 differed profoundly from untreated cells (Tables 7
and 8, http:yyrelman.stanford.edu). Pretreatment eliminated the
infection-associated induction of GRO-2, GRO-1, IL-8, IL-6, IL-
1b, MCP-1, MIP-1a, GRO-3, CIITA, HLA-DQ, API2yIAP, and
other genes that were induced in untreated cells. However, differ-
ences were also noted in the effects of these two inhibitors.
Dexamethasone failed to block a 2.9-fold infection-associated in-
duction of the antiapoptotic molecule TNFAIP3, whereas salicylate
was inhibitory. Furthermore, dexamethasone pretreatment led to a
4.8-fold infection-associated increase in expression of iNOS, which
was not seen in salicylate-pretreated cells or in the absence of drug
pretreatment. Transcription of IL-1, which has been implicated in
Fig. 1. (a–c) Changes in secreted chemokine abundance after exposure of an
epithelial cell line to B. pertussis for 24 h. Representative data from duplicate
experiments are shown. Assays were performed for IL-8 (a), MCP-1 (b), and IL-6
(c). (d) Migration of neutrophils in response to the supernatants of B. pertussis-
infected epithelial cells. In duplicate experiments, neutrophils migrated to-
ward the supernatant with or without 10 mgyml anti-IL-8 Ab. Migration index
is the ratio of cells that migrated to a supernatant in comparison to the
uninfected supernatant. Error bars represent the 95% confidence interval of
the mean of three wells.
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the induction of iNOS activity (12), was not detected in dexa-
methasone-treated cells.
B. pertussis Binds Mucin and Induces Its Expression by Bronchial
Epithelial Cells. The regulated expression of mucin in the respi-
ratory tract is one innate host defense that respiratory pathogens
must overcome. Given previously published evidence of mucin
gene responses to other respiratory noxious stimuli, we examined
our microarray expression data for responses by the mucin gene
family. MUC2, which encodes a respiratory tract mucin glyco-
protein, was expressed at 1.5-fold increased levels in cells
exposed to B. pertussis, whereas no response was noted for MUC3
(encodes intestinal mucin) and MUC6 (encodes gastric mucin).
These data prompted further investigation by using a system that
is more sensitive to small changes in mucin gene transcriptional
activity. MUC2 and MUC5AC [also shown to be transcribed in
respiratory epithelium (25)] were studied by using epithelial cells
that harbor a stable transfected copy of the MUC2 or MUC5AC
promoter fused to a luciferase reporter gene. Transcription of
MUC2 and MUC5AC increased during the experiment in both a
dose- and time-dependent manner (Fig. 2 a and b). At 6 h, the
highest bacterial dose gave 32-fold (P 5 0.002) and 17-fold (P 5
0.01) increases in MUC2- and MUC5AC-luciferase activities,
respectively. To our knowledge, there have been no previous
descriptions of mucin gene responses to B. pertussis infection.
Given the ability of B. pertussis to induce mucin gene transcrip-
tion, we hypothesized that the bacterium might be capable of
binding mucin. Fig. 2c shows that B. pertussis adhered to microtiter
plates at 4-fold higher levels when the wells were coated with bovine
salivary mucin and then treated with a nonspecific blocking agent
(nonfat dry milk) than they did to wells treated with the blocking
agent alone (P , 6 3 10212). A related species, Bordetella bron-
chiseptica has been shown to bind to swine nasal mucosa sialyl
glycoconjugates, including mucin (26). Evaluation of several glyco-
conjugates revealed that a sialic acid-containing ganglioside mix-
ture was able to inhibit B. pertussis binding to mucin by 32% (P ,
0.005). N-acetyl-neuraminic acid blocked binding better than N-
acetyl-D-glucosamine, but neither produced a significant decrease
(22% and 12%, P values of 0.07 and 0.32, respectively). These data
suggested that binding of B. pertussis to mucin is mediated by sialic
acid-containing compounds.
Discussion
The use of high-density DNA microarrays to survey genome-
wide transcriptional responses in host cells after exposure to
microbial pathogens is a powerful approach to understanding
host–pathogen interactions (10, 27, 28) (J. Corbeil, D. Genini, D.
Sheeter, S. Rought, L. Leoni, P. Du, M. Ferguson, D. R. Masys,
J. B. Welsh, J. L. Fink, et al., personal communication). Our data
provide an overview of the interaction between B. pertussis and
respiratory epithelial cells at the level of gene transcription and
suggest a number of testable hypotheses. Our studies have
revealed a dominant proinflammatory state in B. pertussis-
exposed bronchial epithelial cells and the induction of host
defenses that might be coopted or subverted by this pathogen. In
addition, we have documented responses by a number of genes
that were not previously known to be associated with B. pertussis
or its virulence factors.
As with any model system, our experimental design and data
have limitations. Transformed cell lines may respond in a manner
distinct from that of primary cells by virtue of altered controls on
growth and differentiation. Furthermore, we are limited by data
from only a single time point and a single multiplicity of infection.
Our system is also limited by the presence of only one cell type,
whereas in an infected host, the responses of bronchial epithelial
cells would be modified by the presence of other immune and
nonimmune cells and a wide variety of soluble factors. These
limitations were accepted to create an easily controlled, easily
manipulated, and reproducible model of the interaction between
B. pertussis and its primary target cell.
B. pertussis-Infected Bronchial Epithelial Cells Exhibit a Transcrip-
tional Profile Dominated by a Proinflammatory Response. Eight of the
thirty-three genes that met our induction criteria on B. pertussis
infection encode proinflammatory cytokines. This host response
profile has not been described previously for B. pertussis infection.
Although the chemokines IL-8, GRO-1, GRO-2, and GRO-3 are
strong neutrophil chemoattractants, MCP-1 and SCYA3 promote
monocyte infiltration (19, 20, 29). IL-8, GRO-1, and SCYA3 have
also been shown to exert lymphocyte chemoattractant properties
(30, 31). These results help to explain the infiltrate seen in autopsy
studies of humans with pertussis and in animal models of the disease
(1, 2). Furthermore, IL-8, MCP-1, and GRO-1 are known to
promote expression of CD11byCD18 (CR3) on the surface of
neutrophils and monocytes (32, 33). This leukocyte integrin is a
receptor for the major adhesin of B. pertussis, filamentous hemag-
glutinin (34). However, the binding of B. pertussis to leukocytes is
not necessarily detrimental to this pathogen: the organism inhibits
oxidative burst and intracellular killing and instead up-regulates its
own binding to these cells and inhibits antigen-dependent T cell
proliferation (34, 35). This suggests B. pertussis has adapted to the
inflammatory response that it elicits from bronchial epithelial cells.
The NFkB Pathway Is Activated in B. pertussis-Infected Cells Without
Evidence of Apoptosis. Our study of human bronchial epithelial cells
indicates that activation of NFkB and downstream pathways are
dominant features of B. pertussis infection, as has been implicated
in other infections (27, 36). The use of dexamethasone and sodium
salicylate support this finding, because both inhibit NFkB activa-
tion, and they abolished the responses of genes which we propose
were induced by NFkB. TRIP, which inhibits NFkB activation, is
down-regulated on infection, thereby allowing NFkB activation
(37). Furthermore, the transcriptional changes in TNFAIP3, API2,
and BTF are suggestive of antiapoptotic signaling, despite the
previous findings of B. pertussis-induced apoptosis in monocytes
and neutrophils (17). In addition, our use of a phenotypic marker
for apoptosis, the appearance of mono- and oligonucleosomes,
Fig. 2. (a and b) Induction of mucin reporter genes by B. pertussis infection. In
duplicate experiments, an epithelial cell line carrying a mucin-luciferase reporter
gene fusion was exposed to varying numbers of B. pertussis for increasing periods
of time. Representative data from one experiment in which the fusion contained
the promoter from MUC2 (a) or the promoter from MUC5AC (b) are shown. (c)
Binding of B. pertussis to mucin-coated plates. One set of data from triplicate
experiments that demonstrates binding of B. pertussis to mucin-coated and
blocked wells vs. those coated with blocking agent alone. Background fluores-
cence of the mucin and nonfat milk are demonstrated by the third and fourth
bars. Error bars represent the 95% confidence interval.
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revealed no evidence of apoptosis in the infected cells after 3 h.
Thus, B. pertussis may have evolved specific mechanisms for killing
inflammatory cells while sparing the nonciliated epithelium on
which it survives.
PT-Responsive Genes Present Clues to the Pathogenesis of Pertussis.
Our use of a catalytically inactive toxin and a strain bearing this
mutant toxin allowed us to investigate the role of the ADP–
ribosyltransferase activity of PT without the confounding effects
of other PT-associated activities. In BEAS-2B cells, two colla-
genases, fibroblast activation protein and matrix metal-
loproteinase I (MMP-1) were transcriptionally down-regulated
by the enzymatic activity of PT. MMP-1 transcription is in-
creased by other infections (38) and by basic fibroblast growth
factor (39), whose transcription was increased by PT catalytic
activity. Down-regulation of MMP-1 expression appears to be an
active process and one that is unexpected. An examination of the
responses elicited by this toxin on other cell types will likely
reveal many other G-protein-linked genes.
Transcriptional analysis suggests that the quantity and quality
of respiratory secretions are altered by the ADP–ribosylase
activity of PT. The product of the down-regulated VIP gene
increases secretion of Cl2 in epithelial cells (40). In the lung,
serotonin mediates airway reactivity and causes fluid transport
across the epithelium into the tracheal lumen (41). Serotonin is
cleared by a transporter, whose gene, SLC6A4, is up-regulated
by PT. Through these regulatory events, B. pertussis may modify
the physical properties of the respiratory tract mucus. This is
borne out by descriptions of thick tenacious mucus at autopsy.
Inhibition of NFkB Activation by Antiinflammatory Agents Has Ther-
apeutic Implications. Previous studies have proposed that cortico-
steroids may have some benefit in the treatment of pertussis
through their effect on transcription of proinflammatory effectors
such as IL-1b, IL-6, and IL-8 (22). Of particular interest given the
role of iNOS in epithelial cell pathology (12) was the finding that
dexamethasone treatment before infection led to increased tran-
scription of iNOS. Other studies have described a decrease in iNOS
transcription when cells are treated with corticosteroids before
stimulation with lipopolysaccharide and several cytokines (42). In
our study, iNOS transcriptional activation occurred despite the
induction of TNFAIP3 expression; in some cells, TNFAIP3 blocks
transcription of iNOS (14). Thus, our data indicate the dominance
of other positive regulatory factors on iNOS expression. From the
perspective of disease management, these data may suggest caution
in the use of corticosteroids for patients with whooping cough.
These agents are predicted to worsen TCT-mediated induction of
iNOS and subsequent adverse effects on neighboring ciliated
epithelial cells.
B. pertussis Subverts the Mucociliary Escalator. Although mucus is
often considered a host defense; in some diseases, such as
asthma, bronchitis, and cystic fibrosis, it contributes to the
pathology. Our data show that B. pertussis, like many other
infectious agents or irritants, is capable of inducing mucin
transcription. With an intact mucociliary escalator, mucin pro-
vides an important housekeeping function. However, lipopoly-
saccharide, in combination with TCT of B. pertussis, paralyzes
ciliated epithelial cells and causes their death and extrusion (6),
leading to a buildup of respiratory secretions. As described
above, PT-induced alterations in VIP and serotonin signaling
could lead to thicker and even more tenacious mucus. We have
demonstrated that B. pertussis is able to bind to mucin, suggesting
that the pathogen may be manipulating host defenses to create
a favorable microenvironment for itself.
Conclusion. Transcriptional analysis of infected epithelial cells has
helped to reveal the mechanisms by which the host responds to B.
pertussis and some of the mechanisms by which this pathogen
attempts to subvert host defenses. Our data help to integrate
preexisting information about the pathology of pertussis, patho-
gen–host and receptor–ligand interactions, and host cell pheno-
types, with virulence mechanisms. A more comprehensive exami-
nation of transcriptional responses of pathogens and their hosts will
help define conserved and specific strategies used by both.
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